Aesica recruits new Business Development Manager to aid sales drive across German, Austrian and Swiss Markets
Aesica has appointed Nadine K. Reuter to the position of Business Development Manager, Finished Dose with responsibility for assisting in the drive to expand revenues from contract manufacturing activities across Germany, Austria and Switzerland. The new role encompasses growing new business, both by working closely with existing customers and through the development of new customer relationships, in addition to raising the profile of Aesica across the region.
Based in Germany, Nadine’s primary focus consists of marketing formulation development, finished dose commercial manufacturing and packaging services to current and new customers in the countries concerned.
Prior to joining Aesica, Nadine K. Reuter worked in Germany as Head of Sales and Business Development, Life Sciences, at Esau & Hueber GmbH, a member of the Bauer Group. Prior to this, she served as Sales Manager at NNE Pharmaplan, targeting pharmaceutical and biotechnology companies in the German and Austrian regions. Earlier, she worked as a Sales Engineer in the biopharmaceuticals division of Pall Corporation focused on the Bayern and Baden Württemberg areas.
Commenting on Nadine K. Reuter’s appointment, Ian Muir, Managing Director, Finished Dose at Aesica commented: “We are delighted that Nadine has joined our European sales team and she will play an important role in driving sales and business growth in the region. We already enjoy significant business and client servicing, carried out from our German sites, located in Zwickau and Monheim, and look forward to utilising Nadine’s sales expertise and knowledge in formulation development, finished dose manufacture and packaging, to help drive new business from existing and new customers located in the countries concerned.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.